70 likes | 183 Views
Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial. Hisao Ogawa et al. JAMA 2008;300:2134-2141. Baseline Clinical Characteristics – Part I. Hisao Ogawa et al. JAMA 2008;300:2134-2141. Baseline Clinical Characteristics – Part II.
E N D
Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:2134-2141
Baseline Clinical Characteristics – Part I Hisao Ogawa et al. JAMA 2008;300:2134-2141
Baseline Clinical Characteristics – Part II Hisao Ogawa et al. JAMA 2008;300:2134-2141
Atherosclerotic Events Hisao Ogawa et al. JAMA 2008;300:2134-2141
Total Percentage of Atherosclerotic Events According to Treatment Group Hisao Ogawa et al. JAMA 2008;300:2134-2141
Subgroup Analysis of Incidence of Atherosclerotic Events Hisao Ogawa et al. JAMA 2008;300:2134-2141
Adverse Effects Hisao Ogawa et al. JAMA 2008;300:2134-2141